Nogapendekin alfa inbakicept (Anktiva)
Protein / enzyme therapeutic
Also known as ALT-803
Evidence outlook
Approved: Bladder Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USPancreatic Cancer · Phase 2 · investigational in the US
Also approved (2)
- Conditional authorisation: with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ
- ANKTIVA with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03022825 NCT03022825 · Bladder Cancer Registry: NCT03022825 | 2/3 | Complete Response (60 Months); Disease-Free Rate (12 Months) 2024-10-01 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (36)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (32)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (20)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Bladder Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nogapendekin Alfa Inbakicept (Anktiva): this drug | Approved | Protein / enzyme therapeutic | IL-15 superagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Enfortumab Vedotin | Approved | Antibody–drug conjugate | Nectin-4 | Partial signal | NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74) NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Cetrelimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Phase 3 | Monoclonal antibody | CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Visugromab | Phase 2 | Monoclonal antibody | GDF-15 | Weak signal | NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%. | |
| MK-3120 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2005 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Tuvutromstat | Phase 1 | Small molecule | MAT2A | not yet graded | No reviewed efficacy summary in this indication | |
| Avipendekin Pegol | —(overall) | Cytokine | IL-15 receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(22 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Nogapendekin alfa inbakicept (Anktiva) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
November 2026 (1)
What to watch
December 2026 (2)
What to watch
What to watch
2027 (7)
March 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
October 2027 (1)
What to watch
2028 (5)
January 2028 (1)
What to watch
February 2028 (1)
What to watch
May 2028 (1)
What to watch
June 2028 (1)
What to watch
September 2028 (1)
What to watch
2029 (4)
January 2029 (1)
What to watch
April 2029 (1)
What to watch
August 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (2)
September 2030 (1)
What to watch
December 2030 (1)
What to watch
2032 (1)
July 2032 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent